Shopping Cart
Remove All
Your shopping cart is currently empty
Ro24-7429 is an effective and orally active antagonist of HIV-1 transactivator protein Tat and an inhibitor of a runt-related transcription factor 1. Ro24-7429 has anti-HIV, antifibrotic, and anti-inflammatory effects.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $84 | In Stock | In Stock | |
| 5 mg | $197 | In Stock | In Stock | |
| 10 mg | $313 | In Stock | In Stock | |
| 25 mg | $533 | In Stock | In Stock | |
| 50 mg | $768 | In Stock | In Stock | |
| 100 mg | $1,080 | In Stock | In Stock | |
| 500 mg | $3,028 | 6-8 weeks | 6-8 weeks | |
| 1 mL x 10 mM (in DMSO) | $226 | In Stock | In Stock |
| Description | Ro24-7429 is an effective and orally active antagonist of HIV-1 transactivator protein Tat and an inhibitor of a runt-related transcription factor 1. Ro24-7429 has anti-HIV, antifibrotic, and anti-inflammatory effects. |
| Targets&IC50 | C8166 cells:0.7 μM |
| In vitro | Ro24-7429 (50-200 μM; 24-72 hours) strongly inhibits the proliferation of A549 and HLF cells in a dose-dependent manner. Ro24-7429 treatment (75 μM) significantly reduces TNF-α-induced up-regulation of RUNX1 mRNA by 50% at 48 hours[1]. Ro 24-7429 (1-25 μM) induces apoptosis and inhibits antigen-induced lymphocyte proliferation. Ro 24-7429 (0.1 μM, 1 μM, 5 μM; 3 days) induces apoptosis of cultured PBMCs in a dose-dependent manner[2]. |
| In vivo | Ro24-7429 (17.5-70 mg/kg; i.p.) curbs expression of fibrosis markers in injured mouse lungs. Ro24-7429 robustly ameliorates lung fibrosis and inflammation in the Bleomycin-induced pulmonary fibrosis mouse model[1]. |
| Synonyms | Ro-24-7429, Ro 24-7429, Ro 247429 |
| Molecular Weight | 272.73 |
| Formula | C14H13ClN4 |
| Cas No. | 139339-45-0 |
| Smiles | CNC1=Nc2ccc(Cl)cc2C(=NC1)c1ccc[nH]1 |
| Relative Density. | 1.36g/cm3 |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 140 mg/mL (513.33 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (14.67 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.